In a statement Pfizer Inc said, it is recalling some batches of blood pressure drug Accuretic and two authorized cheaper versions of the drug citing the presence of elevated levels of a nitrosamine, a potential carcinogenic. Pfizer said it has not received… Read More ›
Belgian drugmaker Galapagos NV has named former Johnson & Johnson senior executive Paul Stoffels as its CEO, effective from April 1, 2022. Since 2012, Stoffels was the chief scientific officer at Johnson & Johnson and has spearheaded the development of its single-shot… Read More ›
In a statement, Bristol-Myers Squibb Co and Eisai Co said, they had entered into an agreement to jointly develop and market an experimental cancer drug worth up to $3.10 billion. Bristol-Myers would pay $650 million, including for research and development… Read More ›
In a statement, the U.S. Department of Justice stated, Gilead Sciences Inc has agreed to settle allegations that it improperly used the Caring Voice Coalition as a conduit to cover thousands of patients’ co-payment obligations and has agreed to pay… Read More ›
The U.S. Justice Department has charged Teva Pharmaceutical Industries Ltd with charges including colluding to conspire with competitors to raise prices of widely used generic drugs, high cholesterol drug. “Today’s charge reaffirms that no company is too big to be… Read More ›
The deal sees Britain’s AstraZeneca Plc led by Pascal Soriot sharing development and commercialization costs for the drug worldwide. For AstraZeneca the deal makes sense as it will replenish its pipeline as its cancer drug sales grow. In a significant… Read More ›
The game changing method founded by researchers Tasuku Honjo and James Allison was used to create the drug Opdivo which was co-developed by Ono Pharmaceutical Co and Bristol-Myers Squibb Co. On Tuesday, shares of Japanese drugmaker Ono Pharmaceutical Co touched… Read More ›
Sanofi’s strength in molecular oncology is likely to provide it a competitive edge over its peers as to what drives the growth of cancer tissues, how these cells functions and proliferation in the body. In a strategic development, French drugmaker,… Read More ›
The elevation of key human resource personnel to Novartis’s board suggests that Vas Narasimhan is aiming to turn a new leaf at the Swiss pharmaceutical giant. Vas Narasimhan, Novartis’s new CEO is strategically changing the leadership in the Swiss drugmaker…. Read More ›
manageria.biz 